Latest Convertible Notes News

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

Patagonia Lithium has reported strong assay and porosity results from its Formentera project in Argentina, alongside a successful $2.79 million capital raise that lifts its cash position to $3.4 million. The company is advancing drilling, seismic surveys, and plans for a 1,000 tonne lithium carbonate demonstration plant.

Terramin Australia has advanced its flagship Tala Hamza Zinc Project into early development with strong Algerian government backing and a revised 2.0Mtpa mining study. Meanwhile, a court ruling returned the Bird in Hand Gold deposit to the company, prompting strategic reviews, all while the group manages a tight cash position supported by a recent $1 million share placement.

Invion Limited is broadening its non-melanoma skin cancer trial to include basal cell carcinoma patients following encouraging safety and efficacy data from squamous cell carcinoma cohorts, targeting the largest skin cancer segment.

MyEco Group has locked in $0.92 million through its Series 2 convertible note program, reinforcing its growth trajectory with funding earmarked for a new GRS-certified recycled bin liner range. The raise supplements a solid cash position while aiming to limit shareholder dilution amid challenging market conditions.

Highfield Resources (ASX:HFR) has dismissed any undisclosed material information as the cause of its recent share price jump, attributing the volatility to global geopolitical tensions impacting fertiliser raw materials.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

HITIQ Limited has drawn down a $1 million loan from a major shareholder associate, with plans to convert the debt into convertible notes subject to shareholder approval. The initial tranche aims to bolster working capital amid ongoing capital market challenges.

Carbonxt Group has secured $750,000 through convertible notes from major shareholder Phelbe Pty Ltd, targeting expansion of its Minnesota pellet manufacturing and increasing its New Carbon Processing stake to 48.1%.

Neurizon Therapeutics has secured an additional A$2.7 million through a placement addressing the shortfall from its entitlement offer, lifting total proceeds to approximately A$8.5 million. This fresh capital strengthens the biotech’s balance sheet and provides financial flexibility as it advances its lead ALS drug NUZ-001 through pivotal clinical stages.

New Hope Corporation is raising A$300 million through a new convertible notes issue while simultaneously seeking to repurchase its existing A$300 million notes. The move coincides with elevated thermal coal prices amid Middle East tensions and ongoing operational guidance.

Telix Pharmaceuticals has initiated a US$550 million convertible bonds offering to refinance existing 2029 bonds and support general corporate purposes, securing low-cost, non-dilutive financing with a conversion premium above current share price.